8-K: Protagonist Therapeutics Secures $300 Million Deal with Takeda, Reports Positive Clinical Progress

Protagonist Therapeutics announced a significant collaboration with Takeda Pharmaceuticals, a $300 million upfront payment, and positive clinical trial updates for its drug candidates.

Summary

• Protagonist Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting a major collaboration agreement with Takeda Pharmaceuticals for rusfertide, which includes a $300 million upfront payment.
• The company's cash runway has been extended through Q4 2027, factoring in the Takeda payment.
• Two articles were published in the New England Journal of Medicine regarding the Phase 2b FRONTIER 1 study of JNJ-2113 and the Phase 2 REVIVE study of rusfertide.
• Johnson & Johnson initiated an expanded JNJ-2113 clinical development program, including four Phase 3 studies in psoriasis and one Phase 2b study in ulcerative colitis.
• Protagonist achieved $60 million in milestone payments in Q4 related to JNJ-2113.
• The company is on track to complete enrollment for the Phase 3 VERIFY study of rusfertide by the end of Q1 2024, with a potential NDA filing next year.
• Protagonist is also advancing its discovery programs, with an oral peptide IL-17 development candidate expected by year end.
• The company reported a net income of $27.3 million for the fourth quarter of 2023, compared to a net loss of $34.2 million in the same period of 2022.
• For the full year 2023, the net loss was $79.0 million, an improvement from the $127.4 million loss in 2022.
• Cash, cash equivalents, and marketable securities totaled $341.6 million as of December 31, 2023, up from $237.4 million the previous year.

Sentiment

Score: 9

Explanation: The document is highly positive due to the significant collaboration with Takeda, the large upfront payment, positive clinical trial results, and improved financial performance. The company's future outlook is also promising with multiple ongoing clinical programs and discovery efforts.

Positives

• The $300 million upfront payment from Takeda significantly strengthens Protagonist's financial position.
• The collaboration with Takeda validates the potential of rusfertide and provides a clear path to commercialization.
• The $60 million in milestone payments from J&J demonstrates the progress of the JNJ-2113 program.
• The publication of positive clinical trial results in the New England Journal of Medicine enhances the credibility of Protagonist's drug candidates.
• The company's cash runway is extended through Q4 2027, providing financial stability for ongoing research and development.
• The net income of $27.3 million in Q4 2023 is a significant turnaround from the net loss in the same period of 2022.
• The company is advancing multiple clinical programs and discovery efforts, indicating a strong pipeline.

Negatives

• The company reported a net loss of $79.0 million for the full year 2023, although this is an improvement from the $127.4 million loss in 2022.
• Research and development expenses remain substantial at $120.2 million for the full year 2023.
• The company is still reliant on milestone payments and collaborations for revenue.

Risks

• The company's success is dependent on the successful development and commercialization of its drug candidates.
• There are risks associated with clinical trials, including the possibility of unexpected adverse events or failure to meet endpoints.
• The company faces competition from other pharmaceutical companies developing treatments for similar indications.
• The company's ability to earn future milestone payments is not guaranteed.
• The company's financial performance is subject to fluctuations in research and development expenses and collaboration revenue.

Future Outlook

The company anticipates completing enrollment for the Phase 3 VERIFY study by the end of Q1 2024 and potentially filing an NDA next year. They also plan to announce an oral peptide IL-17 development candidate by the end of 2024. The JNJ-2113 clinical development program is expected to expand with additional Phase 3 studies.

Management Comments

• The fourth quarter of 2023 was an extremely busy and productive time for Protagonist, said Dinesh V. Patel, Ph.D., the Company's President and CEO.
• We look forward to completing enrollment of the Phase 3 VERIFY study by the end of Q1 2024, and potentially filing an NDA next year after completion of the 52-week study.
• We are extremely pleased to have joined hands with our new partner Takeda in preparation for the potential commercial launch of rusfertide.
• The JNJ-2113 clinical development program is progressing and expanding in a very impressive way, with four Phase 3 psoriasis studies and a Phase 2b study in ulcerative colitis.
• We believe that JNJ-2113 has the potential to be a major part of the Inflammation & Immunology franchise.
• In drug discovery, we plan to announce an oral peptide IL-17 development candidate by year end, maximizing our presence with first-in-class drug candidates for diseases mediated by the IL-17/IL-23 pathway.

Industry Context

This announcement highlights the growing trend of pharmaceutical companies collaborating to develop and commercialize innovative therapies. The partnership between Protagonist and Takeda is a significant example of this trend, particularly in the area of hematology. The expansion of the JNJ-2113 program also reflects the industry's focus on developing treatments for inflammatory and immunological diseases.

Comparison to Industry Standards

• The $300 million upfront payment from Takeda is a substantial deal, comparable to other significant licensing agreements in the biotech industry, such as the $250 million upfront payment Biohaven received from Pfizer for rimegepant.
• The Phase 3 clinical trial progress for rusfertide is in line with industry timelines for drug development, with a potential NDA filing next year similar to other companies in the space.
• The expansion of the JNJ-2113 program with multiple Phase 3 studies is a common strategy for companies seeking to maximize the potential of their drug candidates, similar to how AbbVie is developing multiple indications for Rinvoq.
• The publication of clinical trial results in the New England Journal of Medicine is a significant achievement, indicating a high level of scientific rigor and credibility, similar to publications by companies like Regeneron and Vertex.
• The cash runway extended through Q4 2027 provides Protagonist with a strong financial position, comparable to other well-funded biotech companies like Alnylam and Moderna.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for future revenue growth.
• Employees will have job security and opportunities for career advancement.
• Patients will have access to potentially life-changing therapies.
• The collaboration with Takeda will provide access to a global commercialization network.
• The company's financial health will improve its ability to meet its obligations to creditors and suppliers.

Next Steps

• Complete enrollment of the Phase 3 VERIFY study by the end of Q1 2024.
• Potentially file an NDA for rusfertide next year.
• Continue the clinical development of JNJ-2113, including the initiation of additional Phase 3 studies.
• Announce an oral peptide IL-17 development candidate by the end of 2024.
• Advance discovery programs for novel oral peptides against various clinically validated biological targets.

Key Dates

Keywords

rusfertide, JNJ-2113, Takeda, clinical trials, milestone payments, polycythemia vera, psoriasis, ulcerative colitis, hepcidin mimetic, IL-23 receptor antagonist, biopharmaceutical, collaboration agreement